DEFA14A: Kiniksa Pharmaceuticals Proposes Redomiciliation from Bermuda to the UK

Kiniksa Pharmaceuticals plans to redomicile from Bermuda to the UK, seeking shareholder approval for the move.

Summary

• Kiniksa Pharmaceuticals is proposing to move its legal domicile from Bermuda to the United Kingdom.
• This change will involve cancelling existing Bermuda shares and issuing new UK shares on a one-for-one basis.
• The company's parent entity will transition from being Bermuda-domiciled to UK-domiciled.
• Shareholder approval is required for the redomiciliation, which will be governed by a scheme of arrangement.
• The company expects to distribute a proxy statement to its shareholders concerning the proposals to be considered by shareholders at the meeting, which will include additional information regarding the Redomiciliation.
• Kiniksa does not anticipate any material impact on its current or future operations as a result of the redomiciliation.
• The redomiciliation is expected to be completed in the second half of 2024, pending shareholder and Bermuda Supreme Court approval.

Sentiment

Score: 7

Explanation: The document conveys a neutral to slightly positive sentiment. The redomiciliation is presented as a strategic move to benefit stakeholders by mitigating potential tax disadvantages, with no expected disruption to operations. The sentiment is tempered by the inherent risks associated with obtaining approvals and executing the redomiciliation.

Positives

• The redomiciliation is intended to mitigate potential adverse effects from global tax initiatives and changes in Bermuda tax law.
• The move is not expected to have any material impact on Kiniksa's current or future operations.
• Shareholders' relative economic ownership in Kiniksa will not change.
• The UK possesses robust legal, accounting and financial industries, which we believe will be integral to our future success.
• Redomiciling to the UK will provide a continuity of legal rights for our shareholders on substantially the same grounds as they enjoy in Bermuda.

Negatives

• The redomiciliation is subject to shareholder and court approval, introducing potential uncertainty.
• The company expects to distribute a proxy statement to its shareholders concerning the proposals to be considered by shareholders at the meeting, which will include additional information regarding the Redomiciliation.

Risks

• The company's ability to obtain shareholder approval for the redomiciliation is not guaranteed.
• The company's ability to satisfy the other conditions to the Redomiciliation on the expected timeframe, or at all, is not guaranteed.
• The company's ability to realize the expected benefits from the Redomiciliation and the occurrence of unanticipated difficulties or costs in connection with the Redomiciliation is not guaranteed.

Future Outlook

Kiniksa expects the redomiciliation to be completed in the second half of 2024, pending shareholder and Bermuda Supreme Court approval. The company does not anticipate any material impact on its current or future operations or business plan.

Management Comments

• We have decided that Bermuda is no longer the most desirable jurisdiction for our principal holding company's place of incorporation.
• We determined that redomiciling Kiniksa's parent company from Bermuda to a country with a more expansive tax treaty with the United States would be in the best interests of shareholders, employees and other stakeholders.
• We believe that moving to the UK via the Redomiciliation is the best available option.

Industry Context

Companies sometimes redomicile to optimize their tax structure, access more favorable legal environments, or align with their operational footprint. This move reflects a broader trend of companies reassessing their domiciles in light of changing global tax regulations.

Comparison to Industry Standards

• Redomiciliation is a strategic move employed by various multinational corporations to optimize tax efficiency and regulatory compliance.
• Many companies in the pharmaceutical and biotechnology sectors, such as Shire (now part of Takeda) and Jazz Pharmaceuticals, have previously redomiciled for similar reasons, often seeking more favorable tax environments.
• The choice of the UK as the new domicile aligns with other companies that have found its legal and financial infrastructure attractive, offering a balance between regulatory oversight and business-friendly policies.

Stakeholder Impact

• Shareholders will have their Bermuda Shares cancelled and receive UK Shares on a one-for-one basis.
• Employees are expected to see no material impact on their roles or the company's operations.
• The company believes the redomiciliation will be in the best interests of shareholders, employees and other stakeholders.

Next Steps

• Kiniksa Bermuda will hold a shareholder meeting to approve the terms of a scheme of arrangement.
• Kiniksa will file a scheme of arrangement with the Bermuda Registrar of Companies, provided shareholder and judicial approval is received.
• The Redomiciliation will then be carried out after the close of trading on the day the scheme of arrangement is deemed effective and before the opening of trading on the following day.

Key Dates

Keywords

redomiciliation, Kiniksa Pharmaceuticals, Bermuda, United Kingdom, shareholder approval, tax, OECD, scheme of arrangement